linjc16/ctgov huggingface dataset:
The Effect of Wild Blueberry Consumption on Glucose Regulation in Healthy Adults

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to determine how wild blueberry consumption affects glucose regulation, gastrointestinal hormones and satiety in healthy adults.

Detailed Description
-----------------
Healthy men and women (ages 21 - 65 years) were recruited to take part in a randomized, placebo controlled crossover design study. Subjects were screened to determine their health status (e.g. height, weight, body mass index, blood pressure and medical history). Subjects were randomly assigned to a sequence of two treatments with two study periods. The treatments are frozen wild blueberries and a placebo developed to match calories and fiber of the frozen wild blueberries. The subjects were asked to avoid high polyphenol foods in their typical diet for 7 days and consume one of the two treatments as a dietary intervention. After the seventh day subjects consumed a test meal along with either the wild blueberry or placebo. Blood was collected to determine glucose and satiety hormone levels.

Official Title
-----------------
The Effect of Wild Blueberry Consumption on Diabetes: Evaluation of Glucose Regulation, Gastrointestinal Hormones and Satiety in Healthy Adults

Conditions
-----------------
Diabetes

Intervention / Treatment
-----------------
* Other: Blueberry
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female Exclusion Criteria: BMI < 20 and > 30 kg/m² Pregnant women or women who plan on becoming pregnant during the study Postpartum women Lactating women Diabetes Mellitus Kidney disease Liver disease GI Disease Certain cancers Smokers Blueberry allergies

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Blueberry<br>150 grams wild blueberries | Other: Blueberry<br>* Blueberry - 150 grams wild blueberries (whole fruit)<br>|
| Placebo Comparator: Placebo<br>Placebo control | Other: Placebo<br>* Placebo - matched for calories and fiber<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glucose (mmol/L) | Plasma glucose | Change from baseline 0 hours and 2 hours |
Complementary Medicine Approaches to TMD Pain Management

Study Overview
=================
Brief Summary
-----------------
This study will determine whether selected complementary approaches to temporomandibular joint (TMJ) pain management-acupuncture are as effective as usual care.

Detailed Description
-----------------
Temporomandibular disorders are characterized by pain and tenderness in the muscles of mastication and/or the (TMJ), limitations of jaw opening often accompanied by deviations in mandibular path, and clicking, popping or grating TMJ sounds. This study will compare the effectiveness of the complementary therapies chiropractic therapy and bodywork therapy to the standard of care for TMJ pain. If these complementary interventions are shown to be effective, the goal is to design and implement a Phase III clinical trial to further evaluate the health consequences and cost of these therapies. Participants will be evaluated at baseline, and 6 and 12 months post-intervention. Clinical examinations, saliva samples to assess salivary cortisol levels, and a series of questionnaires to assess pain and grade of dysfunctional pain, psychological functioning, and other physical symptoms will be used to assess outcomes. The investigators will passively monitor health care utilization within KPNW using clinical, research, and administrative databases.

Official Title
-----------------
Complementary Medicine Approaches to TMD Pain Management

Conditions
-----------------
Temporomandibular Joint Disorders

Intervention / Treatment
-----------------
* Procedure: Acupuncture
* Procedure: chiropractic therapy
* Procedure: bodywork therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Psychologically functional TMD patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Acupuncture|nan|
|Procedure: chiropractic therapy|nan|
|Procedure: bodywork therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Comparison of Bowel Cleansing Methods for Colonoscopy in Hospitalized Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare two regimens of polyethylene glycol(PEG) plus bisacodyl versus PEG alone for bowel preparation in hospitalized patients.

Detailed Description
-----------------
Inadequate bowel preparation may lead to a longer colonoscopy, and to an inability to identify lesions. PEG can provide a rapid orthograde peroral approach to colonic lavage without producing significant fluid or electrolyte changes. Thus PEG is now commonly used for bowel preparation. However, large amounts and unsatisfactory taste of PEG solution are generally poorly tolerated, especially in hospitalized patients who had comorbidity and restricted ambulation. Recently, a new PEG-based bowel cleansing agents became available. It combines PEG with a high dose of ascorbic acid or bisacodyl. Although many studies reported the efficacy of these combined solution for colonoscopy, but efficacy in hospitalized patients was under-recognized.

Official Title
-----------------
Efficacy of Bisacodyl Given as Part of a Polyethylene Glycol-based Bowel Preparation Prior to Colonoscopy in Hospitalized Patients

Conditions
-----------------
Intestine; Complaints

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalized patients for colonoscopy Exclusion Criteria: age under 20 years or over 80 years major psychiatric illness known allergy to PEG serious condition- severe cardiac, renal, or metabolic diseases partial colon resection current acute exacerbation of chronic inflammatory bowel disease functional constipation defined by Rome III diagnostic criteria

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PEG plus bisacodyl<br>Those who taken PEG 4L + bisacodyl 10mg | |
| PEG 4L<br>Those who taken PEG 4L alone | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The efficacy of bowel preparation | Ottawa scale | one day (after colonoscopy) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient's compliance and acceptability | acceptability, Visual Analogue Scale | one day (after injestion of preparation solution) | 
| Patient's compliance and acceptability (2) | stress for ingestion, Stress 0(not) - 4(severe) | one day (after injestion of preparation solution) | 
| Patient's compliance and acceptability (3) | willingness for re-evaluation, 0(very willing) - 4(some) | one day (after colonoscopy) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
polyethylene glycol, bisacodyl
Drug Interaction With Genes in Parkinson's Disease

Study Overview
=================
Brief Summary
-----------------
This observational study aims at identifying gene modifiers of Parkinson Disease (PD) and of treatment response and adverse events of antiparkinsonian drugs. Six hundred PD patients will be followed annually for up to 5 years. A biological collection will be associated with a full clinical assessment of motor and non motor symptoms, medical and treatment history, environmental factors. The association between candidate gene polymorphisms and disease or treatment complications will be analyzed.

Detailed Description
-----------------
Title : Drug interaction with genes in Parkinson Disease Objective: To identify genes associated to disease and treatment complication and response. Number of subjects: 500 Study duration : 6 years Design: Prospective cohort with biological collection Primary objective: Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment. Secondary objectives: Prevalence and incidence of disease or treatment complications Clinical risk factor for disease or treatment complications Biomarkers of disease progression, disease or treatment complications

Official Title
-----------------
Drug Interaction With Genes in Parkinson's Disease

Conditions
-----------------
Parkinson's Disease

Intervention / Treatment
-----------------
* Other: Identification of genes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women, age > 18. Parkinson Disease according to UKPDSBB criteria PD diagnosis < 6 years Informed consent Exclusion Criteria: - Atypical parkinsonism

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Parkinson disease<br>Identification of genes | Other: Identification of genes<br>* Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment.<br>* Other names: polymorphism or haplotype;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All complications of the disease or treatment |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson's disease, Pharmacogenetics, Genetics
The Impact of Placental Factors on Fetal Intrauterine Growth and in Intrauterine Programming of the Metabolic Syndrome

Study Overview
=================
Brief Summary
-----------------
Genetic and environmental factors are believed to play a major role in intrauterine growth and intrauterine programming. We intend to study genetic factors such as Telomere homeostasis, senescence, genomic instability and the presence of Genomic copy number variations in placental tissue from pregnancies complicated with Intrauterine growth restriction(IUGR), Gestational and pre gestational Diabetes, placentas from IVF pregnancies and from normal pregnancies. We also intend to assess these factors in cord blood and maternal blood.

Detailed Description
-----------------
Based on the previous data from our group as well as other laboratories, we postulate that there is a correlation between impaired telomere homeostasis, senescence genomic instability and intra-uterine programming in placentas and in fetuses exposed to suboptimal intrauterine conditions such as hypoxia or hyperglycemia. Improved understanding of the mechanisms that produce the genomic changes in IUGR placentas and their influence on later risks of developing the metabolic syndrome should provide basis for future research that might lead into improved outcome of IUGR fetuses.

Official Title
-----------------
The Impact of Placental Factors on Fetal Intrauterine Growth and in Intrauterine Programming of the Metabolic Syndrome

Conditions
-----------------
Normal Pregnancies

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A diagnosis of Intrauterine growth restriction A diagnosis of Gestational diabetes A diagnosis of pre gestational Diabetes IVF pregnancy Exclusion Criteria: chorioamnionitis meconium stained amniotic fluid A request of the patient for Cord blood retrieval for preservation
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| IUGR pregnancies<br>Pregnancies complicated with IUGR. Fetal growth beneath the 10th percentile | |
| pregnancies with Gestational Diabetes<br>Normal glucose levels before 20 weeks, and positive Oral glucose tolerance test | |
| Pre Gestational Diabetes<br>A diagnosis of Diabetes before pregnancy or elevated glucose levels before 20 weeks. | |
| IVF pregnancies<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of Copy Number Variations |  | 10 yeras | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Telomere length |  | 10 years | 
| Number of copies of mitochondrial DNA |  | 10 years |
Correlation Between Interdialytic Weight Gain and Cardiovascular Diseases in Children With End-Stage Kidney Disease Undergoing Hemodialysis

Study Overview
=================
Brief Summary
-----------------
This study aimed to discuss the correlation between interdialytic weight gain and cardiovascular diseases in children with end-stage kidney disease undergoing chronic hemodialysis. The cardiovascular parameters used include left ventricular hypertrophy, systolic and diastolic function, carotid intima-media thickness, myocardial circumferential strain, and strain rate.

Official Title
-----------------
Correlation Between Interdialytic Weight Gain and Cardiovascular Diseases in Children With End-Stage Kidney Disease Undergoing Hemodialysis

Conditions
-----------------
End Stage Renal Disease on Dialysis

Intervention / Treatment
-----------------
* Other: interdialytic weight gain


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: End-stage kidney disease (chronic kidney disease stage 5) Undergo hemodialysis at least twice a week Exclusion Criteria: History of congenital heart disease Critically ill patients with unstable hemodynamic status

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: interdialytic weight gain|interdialytic weight gain during hemodialysis|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between interdialytic weight gain and cardiovascular diseases in children with end-stage kidney disease undergoing hemodialysis | Correlation between interdialytic weight gain and cardiovascular diseases in children with end-stage kidney disease undergoing hemodialysis | Through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
interdialytic weight gain, cardiovascular, chronic kidney disease, hemodialysis
Performance During Menstrual Cycle

Study Overview
=================
Brief Summary
-----------------
This project aims to investigate if muscle strength and muscle power fluctuate during the menstrual cycle. The hypothesis is that the greatest performance will be measured right before ovulation, and at it's lowest on day 1 and 2 of the menstrual cycle in women not using any form for hormonal protection. And that the performance in women using birth control pills, not will variated in the period where they are taking pills (day 1-21).

Official Title
-----------------
Variation in Performance During Menstrual Cycle

Conditions
-----------------
Performance

Intervention / Treatment
-----------------
* Other: estrogen level


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women 18-35 years of age BMI 18.5-25. Exclusion Criteria: Smoking hormonal or metabolic disorders chronic sickness use of medication breast feeding, vegetarians diet containing a lot of soja based products injuries which make it impossible to do the tests

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Women using birth control<br> | Other: estrogen level<br>* Women are tested at different times in their menstrual cycle, if there is a cohesion between performance and level of estrogen<br>* Other names: Physical tests;|
| Women not using birthcontrol<br> | Other: estrogen level<br>* Women are tested at different times in their menstrual cycle, if there is a cohesion between performance and level of estrogen<br>* Other names: Physical tests;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in jumping height | measuring of change in muscle power | 8 times per month, 2 to 5 days between measurements | 
| Change in grip strength | measuring of changes in muscle strength | 8 times per month, 2 to 5 days between measurements | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in hormone levels | measuring of changes in hormone levels during cycle | 8 time per month, 2 to 5 days between measurements | 
| Change in motivation by questionnaire | measuring of changes in motivation for performing | 8 times per month, 2 to 5 days between measurements | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
menstrual cycle, Estrogen, performance, variation
A Double-blinded Evaluation of Safety and Efficacy of Hylaform and Hylaform Plus Compared to Zyplast.

Study Overview
=================
Brief Summary
-----------------
A clinical study to investigate the safety and efficacy of Hylaform and Hylaform Plus for correction of facial wrinkles.

Conditions
-----------------
Facial Wrinkles

Intervention / Treatment
-----------------
* Device: Hylaform, Hylaform Plus (hylan B gel)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: bilateral nasolabial folds with severity score 3 or 4 on the 6-point grading scale Exclusion Criteria: pregnant/lactating women patients who previously received permanent facial implants or using ovet-the-counter products

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Hylaform, Hylaform Plus (hylan B gel)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Non-inferiority as compared to standard of care as assigned by blinded reviewer. |  |  |
Clinical and Biological Study of Sub-pigmentation During Infantile Cystinosis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the molecular mechanism of this disease and to research the relationship between cystinosis and skin phenotype.

Official Title
-----------------
Clinical and Biological Study of Sub-pigmentation During Infantile Cystinosis

Conditions
-----------------
Cystinosis

Intervention / Treatment
-----------------
* Other: analysis of pigmentation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cystinosis known CTNS mutation Exclusion Criteria: patient with corticotherapy treatment patient with immunosuppressant treatment

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 1<br>cutting hair, skin phenotype description | Other: analysis of pigmentation<br>* cutting hair, skin description, skin biopsy for only 4 patients<br>* Other names: skin examination;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to determine molecular mechanism of the disease |  | at time= 0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to research relationship between skin phenotype and cystinosis |  | at time =0 |